Page 4 - South Korean (KOSPI) Pharmaceuticals & Biotech Dividend Stocks

UPDATED Apr 22, 2024

Discover South Korean Pharmaceuticals & Biotech High Yield Dividend Stocks that are on the KOSPI and sorted by Dividend Yield. An upper limit of 20% is in place to filter out stocks with potentially unsustainable dividends. All companies with high dividend yields (above 5%) should be researched for sustainability. For more options please click on ‘Advanced Filters’.

84 companies
CompanyLast Price7D Return1Y ReturnMarket CapAnalysts TargetValuationGrowthDiv Yield

A249420

Ildong Pharmaceutical
₩14,820.002.1%-27.4%₩414.2b₩23,000.00PB2.4xE119.6%0%

A086060

GeneBioTech Ltd
₩3,895.00-0.3%-4.7%₩33.5bn/aPE12.9xn/a0%

A084650

LabGenomics
₩2,720.007.5%-10.5%₩201.9b₩5,000.00PS2.8xS33.3%0%

A003000

Bukwang Pharmaceutical
₩6,140.003.2%-22.0%₩421.7bn/aPS3.3xn/a0%

A420570

J2KBIO
₩16,560.0039.4%n/a₩92.3bn/aPE19.1xn/a0%

A019170

Shinpoong PharmaceuticalLtd
₩13,510.004.0%-25.4%₩720.8bn/aPS3.5xn/a0%

A000520

Samil PharmaceuticalLtd
₩9,270.00-6.1%22.3%₩176.7bn/aPE106.1xn/a0%

A042520

HansBiomed
₩13,220.00-0.2%-7.7%₩171.7bn/aPS2.2xn/a0%

A017180

MYUNGMOON PharmLtd
₩2,050.00-0.5%-19.4%₩68.6bn/aPB0.8xn/a0%

A000250

Sam Chun Dang Pharm
₩100,200.003.2%30.8%₩2.3tn/aPS11.8xn/a0%

A002720

Kukje Pharma
₩5,010.003.0%16.0%₩101.9bn/aPB1.2xn/a0%

A092040

Amicogen
₩7,480.005.9%-9.9%₩408.6bn/aPS2.6xn/a0%
Page 4 of 4
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.